Why these 4 ASX shares have started the week with a bang

The benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has had a positive start to the week and in early afternoon trade is up 0.15% to 6,130 points.

Four shares climbing more than most today are listed below. Here’s why they started the week with a bang:

The Argosy Minerals Limited (ASX: AGY) share price has jumped 14% to 40 cents. Investors have been fighting to get hold of its shares due to the potential of its Rincon Lithium Project in Argentina. In fact, demand has been so strong for its shares that they rose over 1,000% last year. I think Argosy has a lot of promise and is worth keeping a close eye on.

The Auscann Group Holdings Ltd (ASX: AC8) share price has continued its impressive performance with another move higher. The medicinal cannabis company’s shares are up 12.5% to $1.79, bringing its year-to-date gain to an incredible 125%. Whilst I am a big fan of AusCann, I’d be careful buying in at the current share price.

The Cochlear Limited (ASX: COH) share price has risen almost 2% to $175.21 following the release of a positive broker note out of Morgan Stanley. The broker has upgraded its price target on Cochlear to $164 from $146. This is, however, still well below the current share price. I would suggest investors wait in hope of a pull-back to around $150.

The Vocus Group Ltd (ASX: VOC) share price has charged 3.5% higher to $3.25. Although not major news, this morning Vocus announced the appointment of Mr John Ho as a non-executive director. Mr Ho is the founder and chief investment officer of Janchor Partners, a long-term industrialist investor based in Hong Kong. He indirectly holds a 17.9% stake in Vocus.

Missed these gains? Then don't miss out on these blue-chip shares this year. I'm tipping them for big things.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Vocus Communications Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!